Ratings Shanghai MicroPort EP MedTech Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-06-20 EDT			5-day change	1st Jan Change
23.07 ^CNY	-1.91%		-1.37%	-10.06%

04-24	Shanghai MicroPort EP MedTech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-26	Shanghai MicroPort EP MedTech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 296.64 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the past year, analysts have significantly revised downwards their profit estimates.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-10.06%	1.5B		-
QUIDELORTHO CORPORATION	-52.23%	2.36B		C+
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+23.01%	1.94B		-
BIOTAGE AB	+21.24%	1.23B		B+
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-23.46%	880M		-
REVENIO GROUP OYJ	+1.33%	782M		-
CONTEC MEDICAL SYSTEMS CO.,LTD	-34.13%	752M	-	C-
CELLAVISION AB	+23.58%	593M		C+
VAREX IMAGING CORPORATION	-29.66%	589M		B+
BODITECH MED INC.	-22.44%	251M		-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality